These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25499439)

  • 21. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
    Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
    Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
    Blay JY; Leahy MG; Nguyen BB; Patel SR; Hohenberger P; Santoro A; Staddon AP; Penel N; Piperno-Neumann S; Hendifar A; Lardelli P; Nieto A; Alfaro V; Chawla SP
    Eur J Cancer; 2014 Apr; 50(6):1137-47. PubMed ID: 24512981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
    Blay JY; Italiano A; Ray-Coquard I; Le Cesne A; Duffaud F; Rios M; Collard O; Bertucci F; Bompas E; Isambert N; Chaigneau L; Cassier P; Bui B; Decanter G; Derbel O; Coindre JM; Zintl P; Badri N; Penel N
    BMC Cancer; 2013 Feb; 13():64. PubMed ID: 23388156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.
    Stacchiotti S; Verderio P; Messina A; Morosi C; Collini P; Llombart-Bosch A; Martin J; Comandone A; Cruz J; Ferraro A; Grignani G; Pizzamiglio S; Quagliuolo V; Picci P; Frustaci S; Dei Tos AP; Casali PG; Gronchi A
    Cancer; 2012 Dec; 118(23):5857-66. PubMed ID: 22605504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
    Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
    BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
    Penel N; Demetri GD; Blay JY; Cousin S; Maki RG; Chawla SP; Judson I; von Mehren M; Schöffski P; Verweij J; Casali P; Rodenhuis S; Schütte HJ; Cassar A; Gomez J; Nieto A; Zintl P; Pontes MJ; Le Cesne A
    Ann Oncol; 2013 Feb; 24(2):537-542. PubMed ID: 23117071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin.
    Esser M; Kloth C; Thaiss WM; Reinert CP; Fritz J; Kopp HG; Horger M
    Eur J Radiol; 2018 Oct; 107():175-182. PubMed ID: 30292263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
    Ploner F; Lamm W; Schur S; Eisterer W; Kühr T; Lindorfer A; Tinchon C; Köstler WJ; Szkandera J; Brodowicz T
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1337-42. PubMed ID: 23666164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
    Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
    Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Trabectedin registry].
    Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
    Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.
    Ceddia S; Onesti CE; Vari S; Torchia A; Cosimati A; Riva F; Maccallini MT; Cerro M; Benvenuti G; Russillo M; Anelli V; Sperduti I; Biagini R; Ferraresi V
    Front Pharmacol; 2024; 15():1411707. PubMed ID: 39228518
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
    Takahashi M; Takahashi S; Araki N; Sugiura H; Ueda T; Yonemoto T; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Shimura M; Kawai A
    Oncologist; 2017 Aug; 22(8):979-988. PubMed ID: 28526720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution.
    Daupin J; Paubel P; Fillon J; Debrix I; Soares DG; Lotz JP
    J Chemother; 2016 Dec; 28(6):494-499. PubMed ID: 27535294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
    Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S
    Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.